Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

International Journal of Cancer

Volumn 133, Issue 7, 2013, Pages 1653-1663

  Schilling, Bastian ^a   Sucker, Antje ^a   Griewank, Klaus ^a   Zhao, Fang ^a   Weide, Benjamin ^b   Görgens, André ^a   Giebel, Bernd ^a   Schadendorf, Dirk ^a   Paschen, Annette ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

MDSC; melanoma; vemurafenib

Indexed keywords

ARGINASE 1; CD14 ANTIGEN; CD66B ANTIGEN; HLA DR ANTIGEN; LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VEMURAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MALE; MELANOMA; METASTATIC MELANOMA; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE;

MDSC; MELANOMA; VEMURAFENIB;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD14; ARGINASE; CELL ADHESION MOLECULES; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; FEMALE; GPI-LINKED PROTEINS; HLA-DR ANTIGENS; HUMANS; IMMUNE TOLERANCE; INDOLES; MALE; MELANOMA; MIDDLE AGED; MYELOID CELLS; SULFONAMIDES; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 84880294344     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28168     Document Type: Article

References (42)

1. Boon T, Coulie PG, Van den Eynde BJ, et al. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
2. Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010; 70: 4335-45.
3. Nuber N, Curioni-Fontecedro A, Matter C, et al. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. Proc Natl Acad Sci USA 2010; 107: 15187-92.
4. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 2007; 25: 2546-53.
5. Umansky V, Sevko A,. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 2012; 61: 275-82.
6. Greten TF, Manns MP, Korangy F,. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011; 11: 802-6.
7. Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res 2010; 70: 3052-61.
8. Kao J, Ko EC, Eisenstein S, et al. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit Rev Oncol Hematol 2011; 77: 12-9.
9. Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009; 15: 2148-57.
10. Umansky V, Sevko A,. Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol 2012; 22: 319-26.
11. Ostrand-Rosenberg S, Sinha P,. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182: 4499-506.
12. Eruslanov E, Neuberger M, Daurkin I, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2012; 130: 1109-19.
13. Gallina G, Dolcetti L, Serafini P, et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 2006; 116: 2777-90.
14. Diaz-Montero CM, Salem ML, Nishimura MI, et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
15. Brandau S, Trellakis S, Bruderek K, et al. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leuk Biol 2011; 89: 311-7.
16. Rodriguez PC, Ernstoff MS, Hernandez C, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009; 69: 1553-60.
17. Tartour E, Pere H, Maillere B, et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev 2011; 30: 83-95.
18. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008; 14: 5610-8.
19. Gros A, Turcotte S, Wunderlich JR, et al. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res 2012; 18: 5212-23.
20. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005; 353: 2135-47.
21. Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-94.
22. Blank CU, Hooijkaas AI, Haanen JB, et al. Combination of targeted therapy and immunotherapy in melanoma. Cancer Immunol Immunother 2011; 60: 1359-71.
23. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-206.
24. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012; 30: 2375-83.
25. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
26. Ugurel S, Thirumaran RK, Bloethner S, et al. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis. PLoS One 2007; 2: e236.
27. Hoechst B, Ormandy LA, Ballmaier M, et al. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008; 135: 234-43.
28. Schilling B, Harasymczuk M, Schuler P, et al. IRX-2, a novel biologic, favors the expansion of T effector over T regulatory cells in a human tumor microenvironment model. J Mol Med (Berl) 2012; 90: 139-47.
29. Dumitru CA, Moses K, Trellakis S, et al. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol Immunother 2012; 61: 1155-67.
30. Tang S, Lotze MT,. The power of negative thinking: which cells limit tumor immunity? Clin Cancer Res 2012; 18: 5157-9.
31. Ugurel S, Uhlig D, Pfohler C, et al. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immunol Immunother 2004; 53: 551-9.
32. Nagaraj S, Youn JI, Weber H, et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res 2010; 16: 1812-23.
33. Duffy A, Zhao F, Haile L, et al. Comparative analysis of monocytic and granulocytic myeloid-derived suppressor cell subsets in patients with gastrointestinal malignancies. Cancer Immunol Immunother 2013; 62: 299-307.
34. Raber P, Ochoa AC, Rodriguez PC,. Metabolism of l-arginine by myeloid-derived suppressor cells in cancer: mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest 2012; 41: 614-34.
35. Mandruzzato S, Solito S, Falisi E, et al. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182: 6562-8.
36. Roth F, De La Fuente AC, Vella JL, et al. Aptamer-mediated blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 2012; 72: 1373-83.
37. Sinha P, Parker KH, Horn L, et al. Tumor-induced myeloid-derived suppressor cell function is independent of IFN-gamma and IL-4Ralpha. Eur J Immunol 2012; 42: 2052-9.
38. Lechner MG, Megiel C, Russell SM, et al. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J Transl Med 2011; 9: 90.
39. Lechner MG, Liebertz DJ, Epstein AL,. Characterization of cytokine-induced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273-84.
40. Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 2006; 203: 1651-6.
41. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-23.
42. Ahmadzadeh M, Rosenberg SA,. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107: 2409-14.